

# Jeffrey Lieberman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11992217/publications.pdf>

Version: 2024-02-01

48  
papers

8,407  
citations

156536

32  
h-index

242451

47  
g-index

48  
all docs

48  
docs citations

48  
times ranked

13691  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin, 2022, 48, 199-210.	2.3	11
2	Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 223-231.	1.1	2
3	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. American Journal of Human Genetics, 2018, 102, 1185-1194.	2.6	119
4	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	1.2	61
5	Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 214-225.	0.3	164
6	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838
7	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16, 142-170.	1.3	106
8	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. American Journal of Human Genetics, 2015, 97, 576-592.	2.6	1,098
9	Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. American Journal of Human Genetics, 2014, 95, 535-552.	2.6	569
10	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry, 2013, 14, 2-44.	1.3	343
11	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry, 2012, 13, 318-378.	1.3	498
12	The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research, 2011, 128, 166-170.	1.1	73
13	Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research, 2011, 187, 42-48.	1.7	63
14	Two-stage empirical likelihood for longitudinal neuroimaging data. Annals of Applied Statistics, 2011, 5, 1132-1158.	0.5	7
15	Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 293-304.	2.4	21
16	Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. Focus (American) Tj ETQq0 0,4 rgBT /Qverlock 10		
17	Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking. Journal of Clinical Pharmacology, 2010, 50, 73-80.	1.0	27
18	Adjusted Exponentially Tilted Likelihood with Applications to Brain Morphology. Biometrics, 2009, 65, 919-927.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Does switching to a new antipsychotic improve outcomes?. Schizophrenia Research, 2009, 107, 22-29.	1.1	232
20	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research, 2009, 113, 12-18.	1.1	10
21	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. Journal of Behavioral Health Services and Research, 2008, 35, 215-225.	0.6	19
22	Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophrenia Research, 2008, 101, 67-75.	1.1	35
23	Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia. Biological Psychiatry, 2008, 63, 32-41.	0.7	57
24	CATIE and CUtLASS: can we handle the truth?. British Journal of Psychiatry, 2008, 192, 161-163.	1.7	130
25	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 103-111.	0.7	24
26	NCAM1 and Neurocognition in Schizophrenia. Biological Psychiatry, 2007, 61, 902-910.	0.7	80
27	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. Revista De Psiquiatria Clínica, 2006, 33, 7-64.	0.6	9
28	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal of Psychiatry, 2006, 163, 2080-2089.	4.0	247
29	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo. Revista De Psiquiatria Clínica, 2006, 33, 65-100.	0.6	2
30	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 2006, 7, 5-40.	1.3	194
31	Barriers to Employment for People With Schizophrenia. American Journal of Psychiatry, 2006, 163, 411-417.	4.0	390
32	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 2005, 6, 132-191.	1.3	242
33	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry, 2004, 185, 18-24.	1.7	143
34	The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophrenia Bulletin, 2002, 28, 5-16.	2.3	140
35	Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry, 2001, 49, 487-499.	0.7	491
36	Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial. Journal of Clinical Psychopharmacology, 2001, 21, 448-453.	0.7	31

#	ARTICLE	IF	CITATIONS
37	Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. <i>American Journal of Psychiatry</i> , 2001, 158, 518-526.	4.0	574
38	Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 367-374.	2.2	26
39	Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 367-374.	2.2	119
40	Effects of risperidone on auditory event-related potentials in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 299-304.	1.0	112
41	Effects of clozapine on auditory event-related potentials in schizophrenia. <i>Biological Psychiatry</i> , 1998, 44, 716-725.	0.7	209
42	Striatal enlargement in rats chronically treated with neuroleptic. <i>Biological Psychiatry</i> , 1998, 44, 675-684.	0.7	97
43	Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland. <i>British Journal of Psychiatry</i> , 1996, 169, 483-488.	1.7	268
44	Time Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia. <i>Archives of General Psychiatry</i> , 1993, 50, 369.	13.8	406
45	Mood responses of remitted schizophrenics to methylphenidate infusion. <i>Psychopharmacology</i> , 1991, 105, 247-252.	1.5	8
46	Clozapine pharmacology and tardive dyskinesia. <i>Psychopharmacology</i> , 1989, 99, S54-S59.	1.5	58
47	Dopamine Pathophysiology in Tardive Dyskinesia. <i>Psychiatric Annals</i> , 1989, 19, 289-296.	0.1	2
48	Cognitive impairment in tardive dyskinesia. <i>Psychiatry Research</i> , 1985, 16, 331-337.	1.7	43